Xifaxan
FDA Approves Dotarem, a New MRI Agent »
"The U.S. Food and Drug Administration today approved Dotarem (gadoterate meglumine) for use in magnetic resonance imaging (MRI) of the brain, spine and associated tissues of patients ages 2 years and older.
Dotarem is a gadolinium-based"...
Xifaxan
OVERDOSE
No specific information is available on the treatment of overdosage with XIFAXAN (rifaximin) . In clinical studies at doses higher than the recommended dose ( > 600 mg/day for travelers' diarrhea or > 1100 mg/day for hepatic encephalopathy), adverse reactions were similar in subjects who received doses higher than the recommended dose and placebo. In the case of overdosage, discontinue XIFAXAN (rifaximin) , treat symptomatically, and institute supportive measures as required.
CONTRAINDICATIONS
Hypersensitivity
XIFAXAN (rifaximin) is contraindicated in patients with a hypersensitivity to rifaximin, any of the rifamycin antimicrobial agents, or any of the components in XIFAXAN (rifaximin) . Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis [see ADVERSE REACTIONS].
Last reviewed on RxList: 4/19/2010
This monograph has been modified to include the generic and brand name in many instances.
Additional Xifaxan Information
Xifaxan - User Reviews
Xifaxan User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Here is a collection of user reviews for the medication Xifaxan sorted by most helpful.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Women's Health
Find out what women really need.
Updated & New
